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Abstract
Susceptibility to sporadic Parkinson’s disease (PD) is thought to be influenced by both genetic and environmental factors
and their interaction with each other. Statistical models including multiple variants in axon guidance pathway genes have
recently been purported to be capable of predicting PD risk, survival free of the disease and age at disease onset; however
the specific models have not undergone independent validation. Here we tested the best proposed risk panel of 23 single
nucleotide polymorphisms (SNPs) in two PD sample sets, with a total of 525 cases and 518 controls. By single marker
analysis, only one marker was significantly associated with PD risk in one of our sample sets (rs6692804: P=0.03). Multi-
marker analysis using the reported model found a mild association in one sample set (two sided P=0.049, odds ratio for
each score change=1.07) but no significance in the other (two sided P=0.98, odds ratio=1), a stark contrast to the
reported strong association with PD risk (P=4.64610
238, odds ratio as high as 90.8). Following a procedure similar to that
used to build the reported model, simulated multi-marker models containing SNPs from randomly chosen genes in a
genome wide PD dataset produced P-values that were highly significant and indistinguishable from similar models where
disease status was permuted (3.13610
223 to 4.90610
264), demonstrating the potential for overfitting in the model building
process. Together, these results challenge the robustness of the reported panel of genetic markers to predict PD risk in
particular and a role of the axon guidance pathway in PD genetics in general.
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Introduction
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disease only after Alzheimer’s disease. The majority of
cases are sporadicand usuallymanifest symptomsat 50 years orolder
while a small proportion of cases are inherited in Mendelian fashion.
While several known mutations lead to the Mendelian forms of PD
(for a recent review, see [1]), much remains to be uncovered to
understand genetic causes of sporadic PD. A single variant in the
leucine-rich repeat kinase 2 (LRRK2),Gly2019Ser, may explain ,2%
of the sporadic cases [2] and almost as many as 30% of cases in
Ashkenazi Jews and North African Arab populations [3,4]. A
dinucleotide repeat sequence polymorphism in the promoter region
of the a-synuclein gene (SCNA) and a haplotype in the microtubule-
associated protein tau gene (MAPT) are associated with increased PD
risk (for recent meta-analyses of large sample sets, see [5,6]).
Association of various other polymorphisms with PD risk has also
been reported (www.pdgene.org), but requires further validation
before more definitive conclusion can be made as to whether any are
genuine PD risk factors.
Two recent genome-wide association (GWA) studies have
examined about half a million single nucleotide polymorphisms
(SNPs) for their association with PD [7,8]. Although a number of
putative disease markers have been proposed, independent
replication studies have not confirmed any novel, significant
findings [9–14]. Non-replication may be due to false positive
findings in the initial study, which can be exacerbated by massive
multiple testing performed in GWA studies, or various other
possible factors, such as insufficient power, contributed by modest
effect sizes, small sample collections, or genetic heterogeneity [15].
Furthermore, the initial GWA studies only reported results for
single marker analyses and had not investigated interactions of
multiple genetic risk factors that are thought to underpin common
complex diseases such as PD.
Based on the hypothesis that the joint actions of common gene
variants within certain pathways may play a major role in
predisposing to complex diseases, Lesnick and colleagues recently
reported that a combination of SNPs in axon-guidance pathway
genes is a strong predictor of susceptibility to PD, survival free of
the disease, or age at disease onset [16]. After mining a genome-
wide SNP dataset with 443 case control pairs, they identified 1,460
markers in 128 axon-guidance pathway genes. They built several
models, each with 20,40 of the identified markers, that show
significant association with PD (e.g. odds ratios [OR] of 4.6, 15.4
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predicted probability of PD as compared with the first quartile and
P=4.64610
238 for PD susceptibility). Subsequently, they ana-
lyzed another genome-wide SNP dataset and constructed similar
models with largely different SNPs. They observed significant
association of these models with PD as well. Remarkably in a
separate study, they further reported that models of axon guidance
pathway gene variants were also strong predictors of another
neurodegenerative disease, amyotrophic lateral sclerosis (ALS),
with extraordinary statistical evidence (e.g. OR=1739.73 for the
fourth as compared with the first quartile of predicted probability
of ALS, P=2.92610
260 for susceptibility to ALS) [17]. While a
causal connection between the axon guidance pathway and PD is
appealing and the observed significance appears to be exceedingly
strong, this finding remains to be validated for the same markers
and model in an independent sample set. Although the Lesnick et
al. replication model uses SNPs from the same genes as their initial
models, the replication SNPs differ from the original set of SNPs,
thus a bona fide replication is lacking.
Here we chose to validate Lesnick et al’s initial model that was a
strong predictor of PD susceptibility by testing the set of 23 SNPs
from the original report in two independent PD case control
sample sets, with a total of 525 cases and 518 controls (Table 1).
We individually genotyped these markers and then tested the
proposed model for its ability to predict risk to the disease. The
findings and its implication on the method of pathway association
studies are presented.
Results
In their hypothesis generation sample set, Lesnick and
colleagues reported the identification of a PD risk signature
composed of 23 SNPs in the axon guidance pathway [16]. We
individually genotyped these 23 SNPs in two PD case control
sample sets (Table 1), as described in the Materials and Methods.
Except for one marker in the Celera cases (rs17468382:
PHWE=0.0052) and another in the Celera controls (rs17641276:
PHWE=0.012), none of the other markers significantly deviated
from Hardy-Weinberg Equilibrium (HWE) in their genotype
distribution (All PHWE.0.05). As these were relatively mild
deviations from HWE and since we could not discern any obvious
genotype errors, we decided to keep these two markers for further
analysis. Allelic association tests identified one marker, rs6692804,
in GNAI3 on chromosome 1 showing significance in the Thessaly
sample set (P=0.034). Allele frequencies of this marker in the
Celera cases and controls were, however, in the opposite direction
to the Thessaly sample set, rendering the marker non-significant in
a meta-analysis of the combined sample sets (Mantel-Haenszel
Pcombined=0.88, Breslow-Day OR homogeneity P=0.0075).
We then coded each marker individually according to the
genetic model reported in the original paper, ie, additive,
dominant or recessive as presented in Table 2 of the Lesnick et
al. study and examined whether the model reported by Lesnick et
al. would be associated with PD susceptibility in the two sample
sets we tested. A regression score was calculated for each subject
based on the coefficients given in the Lesnick et al. publication
(Figure 1), followed by testing for association with disease status.
No significant association was observed in the Celera sample set at
the 0.05 level, but there was a borderline significance in the
Thessaly sample set (Table 2). Thus, in the latter sample set, there
was an estimated 7% increase (95% CI: 0% to 14%) in the odds of
PD for each one unit increase in the score, and this effect is in the
Table 1. Sample set characteristics.
Celera Sample Set Thessaly Sample Set
Cases Controls Cases Controls
No. Subjects 311 311 214 207
% Female 53.1 53.1 52.3 50.7
AAO (6SD)
* 63.8 (8.9) n/a 64.2 (9.8) n/a
AAO Range 50–87 n/a 32–87 n/a
AAS (6SD)
** 70.1 (8.5) 70.2 (8.5) 69.5 (9.7) 60.0 (16.8)
AAS Range 52–90 52–90 32–93 18–89
*AAO: age at onset in years.
**AAS: age at sampling in years.
doi:10.1371/journal.pone.0002707.t001
Figure 1. Dot plot showing regression scores of individual
cases and controls in the Celera and Thessaly sample sets. A
score was calculated for each individual as the sum of the specified
main and interaction effects shown in Table 2.
doi:10.1371/journal.pone.0002707.g001
Table 2. Association results for the putative axon guidance
pathway model with Parkinson’s risk.
Sample set OR (95% CI) P-value
Celera 1.0 (0.94–1.06) 0.98
Thessaly 1.07 (1.0–1.14) 0.049
note: A score for each subject was calculated based on the coefficients given in
the Lesnick paper.
Odds ratio represents the increase for each one unit change in the score.
doi:10.1371/journal.pone.0002707.t002
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divided the subjects into quartiles according to their score and
found the odds ratios (95% CIs) for the 2
nd,3
rd and 4
th quartiles as
compared to the lowest quartile were 1.44 (0.82 to 2.51), 1.59 (0.91
to 2.77), and 1.83 (1.05 to 3.21) respectively (Table 3).
Additional models in the Celera sample set did not show
association between the 23 markers and PD risk. Specifically, a
logistic regression model which included the 23 main effects and
10 interaction terms as specified by Lesnick et al. but allowed the
coefficients to be estimated by the data in the Celera sample set,
was not significant (Likelihood ratio test P-value for significance of
the model=0.87). By this analysis, only 1 marker, rs16830689,
was significant in the Celera sample set (P=0.049), and another,
rs6692804, in the Thessaly sample set (P=0.027) (Table 4). This
contrasts with the Lesnick et al. dataset where most markers were
highly significant and had very large odds ratios. In addition, we
examined the reported significant SNP-SNP interaction terms
(P,0.05) and found no significant interaction between any of the
10 SNP pairs and PD risk in either of our sample sets (all P.0.05;
Table 5). A backward stepwise selection procedure beginning with
these same 23 main effects and 10 interaction terms terminated
with none of these terms meeting the criteria to remain in the
model. Similar analyses with the Thessaly sample set yielded a
non-significant model when the coefficients for the main and
interaction effects were estimated from the data (Likelihood ratio
test P-value for significance of the model=0.26) while the
backward stepwise selection procedure produced a final model
with rs6492998 as the single term remaining in the model
(OR=0.56, 95% CI 0.34 to 0.93; P=0.026).
In their paper, Lesnick et al. compared the significance of their
axon-guidance pathway SNP models to the significance of SNP
Table 3. Odds ratio analysis for the groups defined by
predicted PD probability in the Thessaly sample set.
Quartile of Predicted
Probability of PD*
Odds Ratio
Estimate
95% Wald
Confidence Limits
P-overall
model**
Lower Upper
1( ,0.476) 1 NA NA 0.18
2 (.476–.510) 1.44 0.82 2.51
3 (.510–.546) 1.59 0.91 2.77
4( ..546) 1.83 1.05 3.21
*Because we didn’t have data in the nominal groups that Lesnick et al. defined
(our predicted probabilities ranged from 0.328 to 0.634), we did not use the
Lesnick et al. groupings. To be able to calculate odds ratios we broke the
predicted probabilities into quartiles and calculated the odds ratios for each of
the groups.
**Wald test with 3 degrees of freedom.
doi:10.1371/journal.pone.0002707.t003
Table 4. Single marker association with Parkinson’s disease risk according to the models from the Lesnick et al. publication.
Gene Symbol rs_Number Model* Celera Sample Set Thessaly Sample Set Lesnick et al.**
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value
CDC42 rs12740705 DOM 0.84 (0.56–1.27) 0.43 1.45 (0.88–2.37) 0.14 0.16 (0.06–0.41) 1.3E-04
CHP rs6492998 DOM 1.24 (0.68–2.26) 0.48 0.46 (0.19–1.10) 0.08 0.21 (0.09–0.47) 1.6E-04
DCC rs17468382 DOM 0.91 (0.32–2.57) 0.86 0.47 (0.05–4.13) 0.50 0.07 (0.01–0.67) 2.1E-02
EFNA5 rs153690 DOM 1.33 (0.62–2.86) 0.46 1.73 (0.70–4.25) 0.23 0.80 (0.29–2.21) 6.7E-01
EPHA4 rs13386128 ADD 1.06 (0.62–1.80) 0.82 1.70 (0.91–3.17) 0.10 16.29 (5.95–44.59) 5.6E-08
EPHB1 rs2030737 DOM 0.87 (0.56–1.33) 0.53 0.79 (0.46–1.35) 0.40 2.60 (1.23–5.51) 1.2E-02
EPHB2 rs10917325 ADD 1.12 (0.64–1.96) 0.68 1.16 (0.55–2.44) 0.68 0.11(0.05–0.28) 1.6E-06
FYN rs6910116 REC 2.22 (0.41–11.8) 0.35 9.86 (0.42–226.) 0.15 59.95 (5.01–717.33) 1.2E-03
GNAI3 rs6692804 REC 2.45 (0.72–8.29) 0.15 0.21 (0.05–0.83) 0.03 0.07 (0.01–0.32) 6.3E-04
GSK3B rs16830689 REC 0.35 (0.12–0.99) 0.05 0.55 (0.19–1.55) 0.26 0.09 (0.02–0.44) 2.9E-03
MRAS rs4678260 ADD 0.83 (0.57–1.19) 0.32 1.06 (0.63–1.78) 0.82 0.97 (0.57–1.65) 9.1E-01
NTNG1 rs11185076 REC 1.12 (0.16–7.57) 0.90 5.32 (0-Inf) 0.98 0.02 (0.001–0.32) 5.7E-03
PAK4 rs17641276 REC 1.38 (0.83–2.30) 0.21 1.15 (0.64–2.04) 0.63 9.55 (3.73–24.43) 2.5E-06
PAK7 rs2072952 ADD 1.31 (0.74–2.32) 0.35 1.14 (0.49–2.63) 0.75 1.70 (0.75–3.90) 2.1E-01
PLXNA2 rs6656034 ADD 0.92 (0.70–1.21) 0.58 0.95 (0.69–1.30) 0.78 2.92 (1.75–4.87) 4.0E-05
PLXNC1 rs2068435 ADD 1.03 (0.73–1.45) 0.86 1.11 (0.73–1.68) 0.62 0.51 (0.25–1.02) 5.5E-02
PPP3CA rs2044041 DOM 0.73 (0.50–1.06) 0.10 1.03 (0.64–1.66) 0.89 5.72 (2.84–11.51) 1.1E-06
RAC2 rs739043 REC 0.72 (0.41–1.29) 0.28 0.81 (0.41–1.59) 0.55 0.16 (0.069–0.39) 4.8E-05
RRAS2 rs2970332 DOM 1.08 (0.47–2.48) 0.85 1.85 (0.56–6.10) 0.31 8.78 (2.45–31.44) 8.5E–05
SEMA5A rs12658266 DOM 1.16 (0.75–1.79) 0.48 1.14 (0.69–1.90) 0.59 0.22 (0.10–0.49) 2.0E-04
SLIT3 rs9688032 DOM 1.00 (0.45–2.22) 0.98 0.70 (0.26–1.86) 0.49 17.46 (4.61–66.07) 2.5E-05
UNC5C rs11097458 ADD 0.84 (0.64–1.11) 0.23 1.00 (0.73–1.36) 0.97 2.25 (1.41–3.61) 7.2E-04
UNC5C rs4444836 DOM 1.15 (0.77–1.72) 0.47 1.10 (0.68–1.77) 0.69 0.38 (0.17–0.85) 1.8E-02
*ADD: log additive; DOM: Mendelian dominant; REC, Mendelian recessive.
**Lesnick et al. PLoS Genet 3(6): e98. Table 1.
doi:10.1371/journal.pone.0002707.t004
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selected from throughout the genome. However, by comparing
their observed results to randomly selected SNPs from the entire
dataset (198k SNPs), they are generating a null distribution
uncorrected for the multiple testing and selection of the most
significant SNPs chosen from among ,1,400 SNPs (the number of
SNPs in the axon guidance pathway) in their dataset. To illustrate
this further, we carried out a simple simulation where 1,400 SNPs
were generated under a null model of independence between
phenotype and genotypes and the most significant SNP was
retained. This selected SNP was plotted alongside a SNP randomly
selectedfrom198kSNPsgeneratedunderthesamenullmodel.This
procedure was iterated 200 times and the results presented in a
histogramofthe 2log10P-value(associationP-value uncorrected for
multiple testing) (Figure 2A). There is a clear difference between the
distribution of P-values from the highly-selected SNPs (from the
1,400 null SNPs) and the randomly-selected SNPs (from 198k null
SNPs) even though they are all generated under the identical null
model. Although this is an oversimplification of the procedure used
by Lesnick et al., it does serve to illustrate how overfitting can occur
from results taken from a large number of tests if correction for
multiple testing is not performed.
In order to generate a null distribution corrected for the
overfitting caused by selection of a model from a large number of
SNPs, we simulated the Lesnick et al. model selection process using
the Fung et al. publicly available Parkinson data [8] (N=540; 269
cases vs 271 controls). We iterated a model selection procedure
very similar to the Lesnick et al. process (details in statistical
methods) 500 times. For each iteration, two datasets were created
from the Fung data: one where the disease status remained intact
for each of the 540 study participants (Observed Method) and one
where the disease status was permuted to randomize the
association of PD among those individuals (Permuted Method).
The selection procedure then generated a final model for each
dataset. The number of individual SNPs achieving univariate
significance (P,0.05) ranged from 82 to 174 for the 500 iterations
of the observed model and from 83 to 174 for the permuted
models. A stepwise logistic regression procedure with selection
from the sets of significant SNPs resulted in final models where the
number of SNPs included ranged from 14 to 58 for the observed
models and from 15 to 57 for the permuted models. Histograms of
the 2log10 P-values for the final models for both selection methods
are shown in Figure 2B. The distribution of P-values for SNP
models from the observed method appears to be indistinguishable
from those of the permuted method and the range of P-values
(3.13610
223 to 4.90610
264) spans the P-value (3.93610
244) from
Table 5. SNP-SNP interaction with Parkinson’s disease risk according to the models from the Lesnick et al. publication.
Interaction Celera Sample Set Thessaly Sample Set Lesnick et al.
Gene-Gene SNP-SNP Odds Ratio (95% CI) Pinteraction Odds Ratio (95% CI) Pinteraction Odds Ratio (95% CI) Pinteraction
DCC*PAK4 rs17468382*rs17641276 3.20 (0.46–21.9) 0.24 1.18 (0.03–37.6) 0.92 0.02 (0.002–0.19) 6.0E-04
EPHA4*FYN rs13386128*rs6910116 0.78 (0.34–1.76) 0.55 0.66 (0.28–1.54) 0.35 0.16 (0.05–0.53) 2.8E-03
EPHA4*PAK7 rs13386128*rs2072952 0.96 (0.59–1.55) 0.88 0.62 (0.36–1.07) 0.09 0.26 (0.11–0.62) 2.7E-03
EPHB2*EFNA5 rs10917325*rs153690 0.90 (0.48–1.68) 0.76 0.66 (0.29–1.49) 0.33 5.25 (2.10–13.13) 4.0E-04
FYN*RRAS2 rs6910116*rs2970332 0.58 (0.10–3.24) 0.54 0.14 (0.00–3.14) 0.22 0.04 (0.003–0.50) 1.3E-02
FYN*SLIT3 rs6910116*rs9688032 0.80 (0.33–1.93) 0.63 0.84 (0.29–2.43) 0.76 4.52 (1.32–15.47) 1.6E-02
MRAS*SLIT3 rs4678260*rs9688032 1.02 (0.60–1.74) 0.92 1.07 (0.56–2.08) 0.82 0.18 (0.08–0.41) 5.9E-05
PAK7*CHP rs2072952*rs6492998 0.75 (0.40–1.39) 0.37 1.40 (0.58–3.36) 0.45 2.94 (1.23–7.01) 1.5E-02
SEMA5A*RAC2 rs12658266* rs739043 1.01 (0.38–2.72) 0.97 0.50 (0.15–1.64) 0.26 4.95 (1.37–17.91) 1.5E-02
UNC5C*DCC rs11097458*rs17468382 0.92 (0.37–2.27) 0.86 1.39 (0.32–5.90) 0.65 6.89 (1.20–39.51) 3.0E-02
doi:10.1371/journal.pone.0002707.t005
Figure 2. Simulation analysis. (A) Histogram of randomly-selected
SNPs and highly-selected SNPs, both generated under a null model and
uncorrected for multiple testing. The selected SNPs were obtained by
taking the most significant SNP from a set of 1,400 null SNPs. The
random SNPs were obtained by randomly-selecting a marker from the
198k SNPs. The 200 presented data points were generated from 200
iterations of the simulation. (B) Distribution of 2log(P-value) for global
likelihood ratio test from the observed method and the permuted
method that mimic Lesnick’s model selection scheme (see Materials and
Methods). P-values were tallied from 500 observed models and 500
permuted models.
doi:10.1371/journal.pone.0002707.g002
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built from SNPs in the axon guidance pathway genes.
Discussion
Findings from GWA studies suggest that individual genetic
variants make very modest contributions to the risk of common
complex diseases, such as type II diabetes and autoimmune diseases
(see, for example, [18–20]). The small genetic effect is in part
responsibleforthe often-reportedfalsepositiveassociations[21] and
dictatesreplicationofinitialfindingsinlarge,oftentensofthousands
of case and control samples. In the case of GWA studies of PD, no
novel genetic markers have been convincingly identified. The
assumption that multiple disturbances in certain pathways lead to
the manifestation of disease is appealing – for example, the amyloid
b pathway hasbeen linkedto mutationsthat cause Mendelianforms
of Alzheimer’s disease [22] and mitochondrial dysfunction and
ubiquitin-proteasomal pathway have been postulated to be key to
PD pathogenesis [23,24]. Lesnick et al. hypothesized that the axon
guidance pathway is critically involved in PD risk and provided a
multi-marker genetic model capable of strongly predicting PD risk
(odds ratio of Q4 vs Q1=90.8, P=4.64610
238). Wang and
colleagues analyzed the same dataset (Maraganore et al. dataset [7])
using a method analogous to the pathway clustering analysis for
micro-arrays. Their analysis also identified axon guidance as the
most significant pathway that showed an over-representation of
disease-associated markers compared to the null hypothesis,
although they did not provide any genetic model with specific
markers [25]. However, the axon guidance pathway did not make
the short list of the most significant pathways in a similar analysis of
another PD dataset (Fung et al. dataset [8], which contains
,400,000 SNPs compared to ,198,000 SNPs in the Maraganore
et al. dataset and is similar in sample size to the Maraganore et al’s
replication sample set) [25]. There might be multiple reasons for
these discrepant findings, including differences in choice of the
genotyped SNPs between two datasets and the possibility of a false
positive result in the Maraganore et al. dataset. Consistent with the
Wang etal.results, we were unable to confirm theputative risk panel
in the Celera sample set which contains overlapping samples with
the Fung et al. dataset (both draw case control samples from the
NINDS Human Genetics Resource). Furthermore, no significant
association was observed after exploring additional genetic models
with the 23 markers.
Although the association of the multi-marker panel with PD risk
showed a borderline replication in the Thessaly sample set, the
association was not nearly as strong as that observed in the
replication sample set used by Lesnick et al. (ORs for 2
nd,3
rd and 4
th
quartiles of predicted probability of PD as compared to lowest
quartile of 1.44, 1.54 and 1.83 in the Thessaly sample set versus
7.86, 16.14 and 121.14 in Lesnick et al.) These results, together with
the non-replication of the putative model in the Celera sample set,
challenge the specific risk model proposed by Lesnick et al. and thus
a genetic contribution of the axon guidance pathway to PD risk in
general. Although Lesnick et al. presented ‘‘replication’’ data in their
initial report, the methods used for replication employed by them
andbyourstudyarefundamentallydifferent.Wetested thesameset
of SNPs and genetic model identified in the hypothesis generation
sample set, whereas Lesnick et al.used different SNPs in the same set
of genes – a main limitation of their study due to the fact that not all
markers typed in their hypothesis generation sample set had been
typed in the replication sample set. In the replication by Lesnick et
al., SNPs were selected through a multi-stage process that involved
the selection process in the hypothesis generating sample set. Such
multi-stage selection procedures employed during both hypothesis
generation and hypothesis validation stages are liable to generate
overfit models (see further discussion later), whereas our replication
of a single model (determined a priori to the study) in independent
sample sets does not generate anti-conservative results.
Considering the extraordinary significance level and effect size
reported in their hypothesis generation sample set, the power to
detect a similar effect even in the relatively modest sample sizes
explored here is extremely high if the reported effect sizes were
genuine or modestly over-estimated. Indeed, Lesnick et al.
estimated that fewer than 100 subjects would have been required
to show significance with the odds ratios they observed (see online
Annotations and Discussions related to the Lesnick et al.
publication [17]). Thus, it seems clear that factors other than
variation due to random sampling are contributing to the lack of
replication, particularly considering the similar demographics of
the Celera sample set we have used in this study. Many factors
may contribute to the negative result in our sample sets, and one
important contributing factor may be that the SNP selection
procedure implemented by Lesnick et al. provides an overly
optimistic fit to the dataset on which the model was developed. In
this regard, it is worth noting that most of the 23 markers showed
highly significant individual association with PD risk and conferred
large effect sizes in the Lesnick et al. dataset. For example, 19
markers had reported OR.2.0 and 13 had OR.5.0, when
additive, dominant, or recessive models were considered. Such
large single marker effects have rarely been observed in common
complex diseases and were not replicated by the individual marker
analysis in our sample sets. Lesnick et al. employed a bootstrap
procedure to compare the significance of their axon guidance
pathway SNP models to that of randomly selected SNP models
and found their models to be significantly better than the
randomly chosen models. However, the hypothesis tested by this
procedure is not the only hypothesis of interest.
Our simulation study shows that SNP selection methods similar
to those of Lesnick et al. can generate models with overly optimistic
risk estimates and P-values. Although our model selection scheme
did not exactly replicate the Lesnick scheme, we believe it is
representative of their method. Differences in our methods
included 1) the handling of missing genotype data: we removed
SNPs with greater than 5% missing data and imputed missing
genotypes for SNPs with #5% missing data, 2) selection of SNPs
for final models: we performed stepwise logistic regression but did
not refine with subsequent backward elimination, 3) we did not
individually add SNPs back into the candidate model using
stepwise selection, and 4) we did not evaluate pair-wise interactions
for inclusion in our final models. Lesnick et al. reported that 183 of
the total 1,460 axon guidance SNPs were individually associated
with PD susceptibility. From these 183 SNPs they produced a final
model containing 23 SNPs and 10 pair-wise interactions with an
overall model P-value of 4.64610
238. Similarly, our simulations
selected a range of 82 to 174 SNPs associated with PD susceptibility
from a range of 1,390 to 1,410 SNPs in randomly selected genes.
Likewise, our simulated models selected a range of 14 to 58 SNPs
from the 82 to 174 individually associated SNPs with overall model
P-values ranging from 4.90610
264 to 3.13610
223. Apparently,
our numbers of selected SNPs and associated P-values from the
models generated from the observed but randomly selected genes
as well as the permuted models are similar to those obtained by
Lesnick et al. This suggests that their final model likely suffers from
overfitting and thus should be compared to a null distribution
generated by a process similar to those we have generated here to
properly account for the model selection process and to provide a
clear context in which to interpret the risk estimates and P-values of
the model.
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that a putative genetic model composed of SNP variants in genes of
theaxonguidancepathwayisastrongpredictorofPDrisk.Wehave
not attempted to determine whether such models are correlated
with disease-free survival or age at disease onset. Our result suggests
that other genetic markers and models need to be tested to
determine whether the axon guidance pathway is critically involved
in PD etiology. In addition, as with reported associations of single
genetic variants, our result underscores the necessity of replication
for multi-marker combinations in genetic association studies [26].
We anticipate that such pathway-based or multi-gene analyses will
become more common following the current wave of GWA studies
[27], thus it is recommended that a vigorous replication be carried
out before any disease association is proposed.
Materials and Methods
Study samples
Two late-onset Parkinson case-control sample sets, with a total
of 525 cases and 518 controls, were used in this study (Table 1).
The Celera sample set was constructed from PD cases and
matched population/convenience controls that are available
through the NINDS Human Genetics Resource at the Coriell
Institute (http://locus.umdnj.edu/ninds). Cases and controls were
matched by age and gender, where 272 pairs have identical gender
and age at sampling; 39 other pairs have identical gender but age
at sampling is within a 3-year interval, with most cases younger
than controls. The Thessaly sample set was obtained from an
outpatient clinic for movement disorders in the Larissa University
Hospital in Central Greece [28]. The cases were matched to
normal subjects living in the same geographical area as the cases.
All cases and controls are white in both sample sets and were
collected with informed consent from the individuals. Cases met
UK Brain Bank criteria for idiopathic PD [29] and controls were
neurologically normal. None of the cases in the two sample sets
carry the Gly2019Ser mutation in LRRK2 [30]. In addition, no
significant population stratification was observed in the NINDS
sample set [31]. Detailed demographics are provided in Table 1.
Markers, assays and genotyping
Themarkerstestedinthisstudyincludethe23SNPsinTable1of
Lesnick et al. [16] that were reported to predict PD susceptibility.
Genotyping assays were developed and validated in-house using the
method of allele-specific real time PCR [32]. DNA samples were
individually genotyped in the Celera high-throughput genotyping
lab. Genotypes were assigned by an automated algorithm, and were
subjected to manual inspection by an individual who had no access
to the study’s phenotype information. To aid in quality control,
HWE testing was carried out for each marker in the two sample sets
individually. Our overall genotyping accuracy was consistently
found to be .99% [33].
Statistical analysis
HWE was evaluated using an exact test as described by Weir
(‘‘Genetic Data Analysis II’’, Sinauer Associates, Sunderland MA,
1996, 2
nd edition). Allelic association of individual markers with
disease status was evaluated using the x
2 test. In order to test
Lesnick’s model to predict PD susceptibility, we first coded each of
the 23 SNPs such that the alternate allele as specified in Table S1 of
Lesnick et al.was modeled in the log additive, dominant, or recessive
coding. Next, for each subject in the dataset, the natural log of the
oddsratios reported inTable 1 of Lesnick etal.wasmultiplied by the
appropriately coded SNP(s) in order to represent the main and
interaction effects of the model. A score for each subject was then
calculated as the sum of the specified main and interaction effects.
We then tested whether the score was associated with PD
susceptibility in a logistic regression model. For each dataset, a
second logistic regression model containing the identical main and
interaction terms was run, but instead of fixing the coefficients
specified by Lesnick et al. we allowed the coefficients to be estimated
from the data. Finally, a backward stepwise selection procedure was
run, with alpha$0.05 as the condition for elimination from the
model, in order to determine if eliminating some of the non-
significant SNPs could result in a better model.
A simple Monte Carlo simulation, written in XLISP-STAT, was
performed for illustration purposes of the overfitting present when
multiple testing is not accounted for. 198k SNPs were generated
under the null hypothesis of independence between case-control
status and genotype count as a source of the randomly-selected
SNP (although 198k SNPs were generated, really only one SNP
was necessary as these were randomly-selected). The selected
SNPs were derived from the most significant SNP from 1,400
SNPs also generated under the null model. Allele frequency
spectrum was derived from a beta distribution similar to those
studied in neutral models of population genetics. The distribution
was then truncated (frequencies were bounded by 2% and 98%) to
model the filtering of SNPs that often occurs on the basis of
frequency for GWA panels. HWE was explicitly used. The
subsequent generation of genotype counts was identical for cases
and controls. A 2-df likelihood ratio test of genotypes between
cases and controls was used to calculate association P-values.
The simulation was iterated 200 times and a randomly-
selected SNP and the most significant SNP were saved after each
iteration.
The publicly available data from Fung et al. [8] was used to
simulate a null distribution which accounts for the potential
overfitting incurred when a model is built using a set of SNPs
selected from among a large set of SNPs. We constructed 500
models using SNPs selected from randomly chosen genes
(Observed Models) and following a selection scheme similar to
that of Lesnick et al. and an additional 500 models by permuting
the disease status of the study participants prior to simulating the
selection scheme (Permuted Models). To begin, 500 datasets were
constructed by serially randomly selecting genes from the Fung et
al. data and including all SNPs from the selected genes until there
were no less than 1,390 SNPs and no more than 1,410 SNPs in the
datasets. From these 500 datasets, 500 parallel datasets were
constructed by permuting the disease status of the study
participants. SNPs with .5% missing genotype data were
eliminated from consideration in the model selection process.
Missing genotypes for SNPs with #5% missing data were imputed
using Hardy-Weinberg genotype frequencies derived from empir-
ical allele frequencies stratified by disease status. For each dataset,
we followed Steps 1, 2, and 3 of Lesnick’s model selection scheme
to select individual SNPs to be included for subsequent selection
into final models. Specifically, genotypes for each of the selected
SNPs were coded as genetically log-additive, Mendelian dominant,
and Mendelian recessive. Logistic regression was employed to
select individual SNPs associated with PD for each genetic coding.
Wald x
2 statistics were recorded for each SNP and those with P-
values.0.05 were removed from further consideration. The
smallest P-value of the three codings for each SNP was identified
and those SNPs with P-values#0.05 were included in a stepwise
logistic regression procedure with the individually associated SNPs
from above used as the set of variables considered for inclusion in
the model. Likelihood ratio tests were performed on the overall
final stepwise models and P-values were recorded for each of the
500 observed models and the 500 permuted models.
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